Evaluation of fruquintinib’s efficacy and safety in refractory metastatic colorectal cancer: a systematic review and meta-analysis of phase II and III randomized controlled trials
- 20 December 2024
- journal article
- research article
- Published by Springer Nature in Clinical Journal of Gastroenterology
- Vol. 18 (1) , 11-22
Abstract
Background Metastatic colorectal cancer (mCRC) remains a significant cause of mortality despite advancements in treatments. Fruquintinib, a potent VEGFR inhibitor, has shown promise as an advanced therapy for mCRC. This review evaluates the efficacy and safety of fruquintinib compared to placebo in patients with refractory mCRC, focusing on Phase II and III trials. Method This study was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. A literature search was performed using PubMed, EBSCOHost, ProQuest, and Google Scholar. The analysis of overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and safety was pooled using hazard ratios (HR) and risk ratios (RR) in RevMan 5.4 software. Results Three RCTs comprising 1,178 patients were included. Fruquintinib significantly improved OS (HR: 0.66; 95% CI 0.57–0.76) and PFS (HR: 0.30; 95% CI 0.26–0.35) compared to placebo. ORR (RR: 5.91; 95% CI 1.09–32.16) and DCR (RR: 3.83; 95% CI 3.00–4.90) were also higher with fruquintinib. Grade 3 or higher adverse events were more frequent with fruquintinib (RR: 1.31; 95% CI 1.02–1.70). No significant difference was observed in serious adverse events or treatment-related deaths. Conclusion Fruquintinib significantly improves survival and tumor response in patients with refractory mCRC. While associated with an increased risk of high-grade adverse events, fruquintinib remains a viable and relatively safe treatment option for mCRC patients. Further studies are needed to confirm its efficacy and safety across diverse populations.Keywords
This publication has 30 references indexed in Scilit:
- Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trialNature Medicine, 2024
- Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence?Expert Opinion on Pharmacotherapy, 2024
- Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 studyThe Lancet, 2023
- Association of Age With Treatment-Related Adverse Events and Survival in Patients With Metastatic Colorectal CancerJAMA Network Open, 2023
- Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO TrialAdvances in Therapy, 2020
- Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?International Journal of Colorectal Disease, 2019
- MA14.05 A Randomized Phase III Trial of Fruquintinib Versus Placebo in Patients with Advanced Non-Small Cell Lung Cancer (FALUCA)Journal of Thoracic Oncology, 2019
- A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysisJournal of Cancer Research and Clinical Oncology, 2019
- Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal CancerJAMA, 2018
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2013